The inaugural ARDS Drug Development Summit will bring 60+ biopharma leaders together to discover how the rise of SARS-CoV-2 ARDS, emergence of novel targets, and the past 12 months of unprecedented global focus on ARDS research has transformed this graveyard of drug development failures into a starting point for the next generation of therapeutics addressing not just ARDS, but broader, systemic inflammation.
Virtually uniting dedicated and experienced industry experts from Aqualung, Bone Therapeutics, Boehringer Ingelheim, Athersys and more, this trailblazing new meeting will help you overcome your most urgent drug development challenges. Unmissable highlights include:
|Discovering how to manipulate the complement cascade with Alexion Pharmaceuticals to streamline the development of clinically effective therapeutics for ARDS|
|Uncovering the implications of long COVID fibrosis for ARDS patients with Boehringer Ingelheim to understand how exactly it effects the lungs and influences the window of therapeutic opportunity for ARDS drug developers|
|Deep diving into the use of human models to predict the pathophysiology of ARDS in COVID-19/none COVID-19 patients with Queens University Belfast so you can strategize your therapeutics development and optimize your chances of getting approval|
|Learning how to design & develop ARDS clinical trials from concept to clinic with Faron Pharmaceuticals in order to know what parameters you must consider to optimize the success of your therapeutic in a clinical setting|
|Exploring novel targeted inhaled therapies for ARDS with Apeptico and hearing how they enhance the mechanism of action aimed at reducing extravascular lung water and reducing inflammation in ARDS patients|